Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vip Trials

Neither a doctor nor a teaching hospital

Research payments

$1,027,458

106 payments

Through program year 2025, Vip Trials is reported as receiving $1,027,458 in research payments, across 106 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $10,213 3
2024 Research $39,228 5
2023 Research $211,579 9
2022 Research $246,194 24
2021 Research $472,113 60
2020 Research $48,131 5

Breakdown

Who paid Research payments · program years 2020–2025
  1. Gilead Sciences, Inc. $381,987 17 payments
  2. Merck Sharp & Dohme Corporation $309,221 7 payments
  3. AbbVie, Inc. $273,896 73 payments
  4. Sumitomo Pharma America, Inc. $30,713 6 payments
  5. Biogen, Inc. $19,892 2 payments
  6. Pfizer Inc. $11,750 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $297,938 5 payments
  2. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $133,059 16 payments
  3. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $119,514 1 payment
  4. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $105,084 1 payment
  5. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $65,028 1 payment
  6. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $49,992 1 payment
  7. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $47,089 11 payments
  8. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $30,713 6 payments
  9. M16-100 $26,044 1 payment
  10. A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $22,889 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record